SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline
Option and license agreement includes multiple fully human bispecific antibodies generated with Biocytogen’s proprietary RenLite® platform Agreement will enable SOTIO to significantly broaden its next-generation ADC portfolio, including multi-specific ADCs Bio






